IL161762A0 - Estradiol inhibiting agents in breast cancer - Google Patents

Estradiol inhibiting agents in breast cancer

Info

Publication number
IL161762A0
IL161762A0 IL16176202A IL16176202A IL161762A0 IL 161762 A0 IL161762 A0 IL 161762A0 IL 16176202 A IL16176202 A IL 16176202A IL 16176202 A IL16176202 A IL 16176202A IL 161762 A0 IL161762 A0 IL 161762A0
Authority
IL
Israel
Prior art keywords
estradiol
breast cancer
inhibiting agents
inhibiting
agents
Prior art date
Application number
IL16176202A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL161762A0 publication Critical patent/IL161762A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16176202A 2001-11-06 2002-11-05 Estradiol inhibiting agents in breast cancer IL161762A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33293901P 2001-11-06 2001-11-06
PCT/US2002/035438 WO2003039466A2 (en) 2001-11-06 2002-11-05 Method of treating estrogen responsive breast cancer

Publications (1)

Publication Number Publication Date
IL161762A0 true IL161762A0 (en) 2005-11-20

Family

ID=23300538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16176202A IL161762A0 (en) 2001-11-06 2002-11-05 Estradiol inhibiting agents in breast cancer

Country Status (6)

Country Link
US (1) US20050002900A1 (xx)
EP (1) EP1450839A4 (xx)
JP (1) JP2005509647A (xx)
CA (1) CA2464529A1 (xx)
IL (1) IL161762A0 (xx)
WO (1) WO2003039466A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002342163B2 (en) * 2001-11-06 2007-11-08 Laboratoires Serono Sa Methods of treating endometreosis
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
AU2005311101B8 (en) * 2004-12-02 2011-03-03 Domantis Limited Anti-IL-IRI single domain antibodies and therapeutic uses
EP1957537A2 (en) * 2005-12-01 2008-08-20 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007095583A2 (en) * 2006-02-14 2007-08-23 Children's Memorial Research Center Methods for treating cancer and sensitizing cancer cells using the serine protease inhibitor, maspin
EP2908843B1 (en) * 2012-11-19 2019-09-04 Agency For Science, Technology And Research Treating cancer
US11110182B2 (en) 2016-12-08 2021-09-07 University Of Cincinnati Multifunctional RNA nanoparticles and methods for treating cancer and therapeutic resistant cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5319071A (en) * 1987-11-25 1994-06-07 Immunex Corporation Soluble interleukin-1 receptors
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US6262239B1 (en) * 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
DE69525181T2 (de) * 1995-07-14 2002-08-14 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6288050B1 (en) * 1997-07-18 2001-09-11 Duquesne University Of The Holy Ghost Steroid sulfatase inhibitors and methods for making and using the same
US6054446A (en) * 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6294655B1 (en) * 1998-04-03 2001-09-25 Hyseq, Inc. Anti-interleukin-1 receptor antagonist antibodies and uses thereof
US6300367B1 (en) * 1999-04-20 2001-10-09 Protein Technologies International, Inc. Composition for and method of preventing or treating breast cancer

Also Published As

Publication number Publication date
EP1450839A4 (en) 2009-06-24
EP1450839A2 (en) 2004-09-01
WO2003039466A3 (en) 2004-01-15
WO2003039466A8 (en) 2004-03-04
US20050002900A1 (en) 2005-01-06
CA2464529A1 (en) 2003-05-15
JP2005509647A (ja) 2005-04-14
WO2003039466A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
HK1083771A1 (en) Anti-neovasculature preparations for cancer
GB0013166D0 (en) Brassiere pad
AU2003222604A8 (en) Proteins involved in breast cancer
EP1277472A4 (en) REMEDIES AGAINST CANCER
EP1476067A4 (en) COMPOSITIONS AND METHODS FOR CANCER
EP1319403A4 (en) TREATMENTS AGAINST CANCER TOLERANT IN CISPLATIN
EP1509539A4 (en) COMPOSITIONS AND METHODS RELATING TO CANCER
EP1694364A4 (en) SYSTEM FOR THE TREATMENT AND PREVENTION OF BREAST CANCER
IL161762A0 (en) Estradiol inhibiting agents in breast cancer
EP1469769A4 (en) NEW COMPOSITIONS AND METHODS AGAINST CANCER
GB0110847D0 (en) Breast cancer detection
GB0005257D0 (en) Breast cancer hormonal therapy
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
EP1469870A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
GB0026015D0 (en) Cancer treatment
EP1530720A4 (en) PROGRAM FOR EXPLOITING BREAST CANCER
AU2002360815A8 (en) Human breast cancer biomarkers
IL154895A0 (en) Seamfree bra
GB0006695D0 (en) Breast cancer markers
AU2002360454A8 (en) Methods and compositions for treating cancer
IL151662A0 (en) Atm mutations in breast cancer
GB0005466D0 (en) Cancer